Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a lysine-analogue, long-acting ACE inhibitor with an in vitro IC50 of 4.7 nM for ACE inhibition under standard assay conditions (pH 8.3, 37°C) (APExBIO, B3290). It reduces the conversion of angiotensin I to angiotensin II, resulting in lowered plasma angiotensin II and aldosterone levels, with increased plasma renin (Tieku & Hooper 1992). The compound is water-soluble (≥2.46 mg/mL) and stable as a solid when desiccated at room temperature. Lisinopril dihydrate is validated for research in hypertension, heart failure, myocardial infarction, and diabetic nephropathy models (Angiotensinii.com). APExBIO provides quality control data including MS and NMR, supporting its use in reproducible experimental workflows.

Biological Rationale

Lisinopril dihydrate is a chemically defined lysine analogue of MK 421, designed to selectively inhibit angiotensin converting enzyme (ACE, EC 3.4.15.1), a key regulator of the renin-angiotensin system (RAS) (Tieku & Hooper 1992). The RAS pathway controls blood pressure and fluid-electrolyte balance through sequential peptide hormone cleavage. ACE catalyzes the conversion of angiotensin I (decapeptide) to angiotensin II (octapeptide), a potent vasoconstrictor that also stimulates aldosterone secretion from the adrenal cortex. Inhibition of ACE reduces angiotensin II-mediated vasoconstriction and sodium retention, thereby lowering systemic blood pressure and cardiac workload. Lisinopril dihydrate’s selectivity and long-acting profile allow for precise modulation of this axis in preclinical models of hypertension, heart failure, and renal pathology. Unlike earlier ACE inhibitors, lisinopril dihydrate is not a prodrug and does not require hepatic activation, leading to more predictable pharmacodynamics (Angiotensinii.com).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds competitively to the active site of ACE, blocking access of angiotensin I to the enzyme’s catalytic zinc ion. The compound’s IC50 for ACE inhibition is 4.7 nM, determined in vitro using purified porcine kidney ACE (APExBIO). This results in a dose-dependent reduction in angiotensin II synthesis, with secondary decreases in plasma aldosterone and increases in plasma renin activity. The inhibition is specific to ACE and does not significantly affect other cell surface zinc aminopeptidases, such as aminopeptidase A, N, or W, as shown by head-to-head benchmarking of metallopeptidase inhibitors (Tieku & Hooper 1992). The compound exerts its antihypertensive effect by promoting vasodilation, reducing peripheral vascular resistance, and decreasing fluid retention. Unlike some ACE inhibitors, lisinopril dihydrate is hydrophilic, resulting in minimal hepatic metabolism and a prolonged plasma half-life suitable for long-acting research protocols (Angiotensin-1-7.com).

Evidence & Benchmarks

• Lisinopril dihydrate demonstrates an IC50 of 4.7 nM for ACE inhibition in vitro (pH 8.3, 37°C) (APExBIO).
• It does not significantly inhibit aminopeptidase A (AP-A), aminopeptidase N (AP-N), or aminopeptidase W (AP-W), ensuring target specificity (Tieku & Hooper 1992).
• In preclinical models, lisinopril reduces plasma angiotensin II and aldosterone, and increases plasma renin, correlating with significant blood pressure reduction (Angiotensin-1-7.com).
• The compound is water-soluble at concentrations ≥2.46 mg/mL when gently warmed and treated with ultrasound (APExBIO).
• High-purity (≥98%) batches are validated by mass spectrometry and NMR, supporting reproducible research use (APExBIO).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely used in basic and translational research targeting hypertension, congestive heart failure, acute myocardial infarction, and diabetic nephropathy models. Its molecular properties allow precise interrogation of the renin-angiotensin system and downstream signaling. The compound’s lack of hepatic activation requirements and high aqueous solubility make it particularly suitable for in vitro and in vivo protocols.

For a broader perspective on molecular selectivity and protocol troubleshooting, see "Lisinopril Dihydrate: Molecular Insights and Emerging Roles", which this article extends by providing updated benchmarks and specificity data. For workflow strategies, consult "Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Research", which is complemented here with new evidence on solubility and purity controls.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate is not effective against non-ACE metallopeptidases; it does not inhibit AP-A, AP-N, or AP-W under standard assay conditions (Tieku & Hooper 1992).
• It is insoluble in ethanol and must be dissolved in water with warming and sonication for optimal results (APExBIO).
• Long-term storage of aqueous solutions is not recommended due to potential hydrolysis; solid material should be kept desiccated at room temperature (APExBIO).
• It is not suitable for studies requiring non-ACE pathway inhibition or for directly modeling non-RAS pathways.
• Clinical outcomes in humans may not be fully replicated in animal models due to interspecies pharmacokinetic differences.

Workflow Integration & Parameters

Lisinopril dihydrate is supplied by APExBIO as a crystalline solid (molecular formula C21H35N3O7, MW 441.52 g/mol). For solution preparation, dissolve to ≥2.46 mg/mL in water, applying gentle warming (≤37°C) and ultrasonic treatment as needed. Avoid use in ethanol or strong organic solvents due to insolubility. Store the dry powder desiccated at room temperature; avoid repeated freeze-thaw cycles. For shipment, the product is provided with blue ice to maintain integrity. Purity (≥98%) is confirmed by Certificate of Analysis, mass spectrometry, and NMR (APExBIO).

Lisinopril dihydrate integrates into standard in vitro ACE activity assays, ex vivo tissue models, and in vivo rodent models of hypertension or cardiac injury. For advanced application guides and troubleshooting, see "Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Research", which provides procedural details that this article updates with new solubility and selectivity insights.

Conclusion & Outlook

Lisinopril dihydrate (B3290) is a validated, long-acting ACE inhibitor with high selectivity and reproducibility, suitable for rigorous research into the renin-angiotensin system, hypertension, and related pathologies. Provided by APExBIO with robust quality control, it offers advantages in solubility, workflow consistency, and molecular specificity. Ongoing research is expected to further expand its applications in cardiovascular, renal, and translational disease modeling, supporting new discoveries in RAS biology and therapy development.

For technical specifications and ordering, visit the Lisinopril dihydrate product page.